Lucid Diagnostics releases data on clinical utility of EsoGuard

Lucid Diagnostics (LUCD), and majority-owned subsidiary of PAVmed Inc. (PAVM), announced it has released positive data from a retrospective analysis demonstrating real-world clinical utility of EsoGuard Esophageal DNA testing for the detection of esophageal precancer in a large cohort of fire fighters. The study documents 100 percent concordance between clinically directed EsoGuard test results and subsequent medical decision-making by the prescribing physician. It demonstrates that EsoGuard can efficiently test large populations at risk for esophageal precancer, allowing physicians to utilize EsoGuard results to appropriately triage those requiring confirmatory endoscopy in a manner broadly consistent with established, and recently updated, professional society guidelines. The manuscript, entitled Clinical Utility of EsoGuard as a Triage Test for Endoscopy to Identify Barrett’s Esophagus in Fire Fighters, has been posted on the leading health sciences preprint server, medRxiv, pending peer review and publication. The release of these data closely aligns with and strongly supports recently proposed federal legislation seeking to fund guaranteed firefighter access to early detection tests such as EsoGuard. “These outstanding results of our first clinical utility study could not be more timely,” said Lishan Aklog, M.D., Lucid’s Chairman & Chief Executive Officer. “We have been gearing up to fully engage with payors for some time and are now armed with excellent clinical utility data and an expanding claims history to support these engagements. The timing aligns with our recent transition to an upgraded revenue cycle management provider, which continues to have a positive impact on claims processing, allowances, and collections..”